Holen Sie sich die Stockscreener-App
97.53
0.34%
-0.33
Handel nachbörslich:
97.53
Schlusskurs vom Vortag:
$97.86
Offen:
$98.37
24-Stunden-Volumen:
1.47M
Relative Volume:
1.21
Marktkapitalisierung:
$194.99B
Einnahmen:
$49.94B
Nettoeinkommen (Verlust:
$17.60B
KGV:
11.43
EPS:
8.53
Netto-Cashflow:
$12.51B
1W Leistung:
-1.56%
1M Leistung:
-1.58%
6M Leistung:
-12.76%
1J Leistung:
-9.91%
1-Tages-Spanne:
$97.45
$98.50
1-Wochen-Bereich:
$97.39
$99.78
52-Wochen-Spanne:
$92.35
$120.92
Novartis Ag Adr Stock (NVS) Company Profile
Vergleichen Sie NVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
97.53 | 194.99B | 49.94B | 17.60B | 12.51B | 8.53 |
|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-04 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-09-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-09-03 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-19 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-09-25 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-26 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-05 | Hochstufung | Stifel | Hold → Buy |
| 2022-09-15 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-05-09 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Fortgesetzt | Citigroup | Buy |
| 2021-12-14 | Herabstufung | Redburn | Buy → Neutral |
| 2021-12-06 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Eingeleitet | Bernstein | Mkt Perform |
| 2021-03-10 | Herabstufung | Argus | Buy → Hold |
| 2021-02-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2020-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-03-10 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-04-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-04-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2018-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Bestätigt | Leerink Partners | Outperform |
| 2017-12-06 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Eingeleitet | Liberum | Buy |
Alle ansehen
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Pain Management Therapeutics Market Is Expected To Reach Revenue Of USD 120.7 Bn By 2033, At 3.9% CAGR: Dimension Market Research. - GlobeNewswire Inc.
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Saudi Arabia Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
South Korea Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Thailand Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
The United States Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
The UAE Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Weekly Upgrades and Downgrades - InvestorPlace
Communiqué de presse - GlobeNewswire Inc.
Are Investors Undervaluing Novartis (NVS) Right Now? - Yahoo Finance
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ - Barchart
Novartis: Time To Increase (NYSE:NVS) - Seeking Alpha
Glaucoma Therapeutics Strategic Industry Report 2024 - GlobeNewswire Inc.
5 high-yielding stocks that best reflect the UN’s Sustainable Development Goals - Equities News
Novartis Canada awards more than $680,000 to community-based programs aimed at advancing health equity - Barchart
5 High-Yielding Stocks Addressing the U.N. Sustainable Development Goals - Morningstar
Novartis Raises Sales Outlook For Mid-Term, Acquires Kate Therapeutics - Barchart
Addressing unmet needs for inherited neuromuscular diseases - Novartis
Inside the Market Dominance of the Top 10 Pharma Giants - Value the Markets
Canada Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
Thailand Antifungal Drugs Market Size & Outlook, 2023-2030 - Grand View Research
MEDIA STATEMENTNovartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment PLUVICTO™ - Barchart
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis
Novartis on Pace for Largest Percent Decrease Since March 2021 — Data Talk - Morningstar
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript - Barchart
Gene Therapy - Novartis
Chemical Biology in Biomedical Research - Novartis
Radioligand therapy: delivering now, building for the future - Novartis
Novartis at ASH - Novartis
Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook - Yahoo Finance
Novartis 2022 Financial Results - Novartis
Novartis Financial Results – Q2 2023 - Novartis
Translational medicine research at Novartis - Novartis
Novartis Financial Results – Q2 2024 - Novartis
Inclusivity - Novartis
Finanzdaten der Novartis Ag Adr-Aktie (NVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
0.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):